Somatuline Depot - 2007 FDA approvals

Drug: Somatuline Depot (lanreotide)
Indication: Acromegaly
Company: Biomeasure
Approval Date: August 30, 2007

Scoop: Somatuline Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom those treatments are not an option. Acromegaly occurs when the pitutary gland produces excess growth hormone. The drug is available in a pre-filled syringe.

Somatuline Depot - 2007 FDA approvals
Read more on

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.